Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 28;25(1):265.
doi: 10.1007/s10238-025-01813-w.

Relative change rate of liver stiffness measurements predicts the risk of liver decompensation in compensated advanced chronic liver disease

Affiliations

Relative change rate of liver stiffness measurements predicts the risk of liver decompensation in compensated advanced chronic liver disease

Yanqiu Li et al. Clin Exp Med. .

Abstract

Patients with compensated advanced chronic liver disease (cACLD) have a significant risk of decompensation. Therefore, this study aimed to evaluate the predictive value of dynamic liver stiffness measurements (LSM) for decompensation risk, and their performance across different clinically significant portal hypertension (CSPH) risk stratification. This retrospective cohort study included 1409 patients with cACLD. Patients were divided into no CSPH, probable CSPH, and certain CSPH groups. Competing risk regression analysis was used to identify the independent predictors. The receiver operating characteristic curve and time-dependent area under the curve were used to evaluate the predictive performance. During follow-up, liver decompensation incidence increased with CSPH severity (22.2% with no CSPH, 37.5% with probable CSPH, and 64.9% with certain CSPH, p < 0.001). Multivariate regression analysis identified age, basal LSM1, delta LSM/LSM1, delta LSM/delta year, spleen diameter, and international normalized ratio as independent risk factors for liver decompensation. In the no CSPH group, spleen diameter showed the best predictive ability (AUC = 0.710). For probable and certain CSPH groups, delta LSM/LSM1 showed superior predictive performance (AUC: 0.777 and 0.782, respectively). The predictive power of basal LSM1 was relatively limited across all groups (AUC: 0.554-0.639). Subgroup analysis revealed interactions between age, sex, different etiologies, and CSPH subgroups. The relative change rate of LSM outperformed basal LSM1 and annual change rate in predicting liver decompensation risk, particularly in patients with existing portal hypertension. Dynamic assessments and differentiated prediction strategies are essential for optimal patient managements.

Keywords: Clinically significant portal hypertension; Compensated advanced chronic liver disease; Dynamic changes; Liver decompensation; Liver stiffness measurement.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: The authors declare no competing interests. Ethical statement: All procedures followed were in accordance with the 1975 Helsinki Declaration, as revised in 2008. The study protocol was approved by the Ethics Committee of Beijing Ditan Hospital (approval number: DTEC-KY2024-069-01). Consent to participate: Informed consent was obtained from all individual participants included in the study.

Figures

Fig. 1
Fig. 1
Dynamic changes in LSM and their relationship with liver decompensation. (a) Distribution of dynamic LSM changes in patients with cACLD. (b) Sankey diagram showing the relationship between baseline CSPH status, LSM dynamic changes, and decompensation outcomes. cACLD, compensated advanced chronic liver disease; CSPH, clinically significant portal hypertension; LSM, liver stiffness measurements
Fig. 2
Fig. 2
Cumulative incidence of liver decompensation based on CSPH status and LSM dynamic changes. a Cumulative incidence of liver decompensation in cALCD stratified by CSPH status. b Cumulative incidence of liver decompensation in cALCD stratified by LSM dynamic changes. c Cumulative incidence of liver decompensation in patients without CSPH stratified by LSM dynamic changes. d Cumulative incidence of liver decompensation in patients with probable CSPH stratified by LSM dynamic changes. e Cumulative incidence of liver decompensation in patients with certain CSPH stratified by LSM dynamic changes. cACLD, compensated advanced chronic liver disease; CSPH, clinically significant portal hypertension; LSM, liver stiffness measurements
Fig. 3
Fig. 3
Prediction value of different predictors for liver decompensation in cACLD patients stratified by CSPH status. ROC curves (a) and time-dependent AUC curves (b) showing the predictive performance of LSM1, delta LSM/LSM1, delta LSM/delta year, spleen diameter, and INR for liver decompensation in patients without CSPH. ROC curves (c) and time-dependent AUC curves (d) for patients with probable CSPH. ROC curves (e) and time-dependent AUC curves (f) in patients with certain CSPH. cACLD, compensated advanced chronic liver disease; CSPH, clinically significant portal hypertension; LSM, liver stiffness measurement; LSM1, basal LSM; INR, international normalized ratio; ROC, receiver operating characteristic curve; AUC, area under the curve
Fig. 4
Fig. 4
Subgroup analyses of the predictive value of basal and dynamic LSM indices for liver decompensation in cACLD patients. Forest plot showing the association between basal LSM1 (a), delta LSM/LSM1 (b), delta LSM/delta year (c) and risk of liver decompensation in different subgroups. N, number of patients in each subgroup; P value, statistical significance for each subgroup association; P for interaction, P-value testing for interaction between the LSM parameter and subgroup variable. cACLD, compensated advanced chronic liver disease; CSPH, clinically significant portal hypertension; LSM, liver stiffness measurement; LSM1, basal LSM; SHR, subdistribution hazard ratio; CI, confidence interval

Similar articles

References

    1. Taru V, Szabo G, Mehal W, et al. Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation. J Hepatol. 2024;81(5):895–910. 10.1016/j.jhep.2024.06.016. - PMC - PubMed
    1. de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74. 10.1016/j.jhep.2021.12.022. - PMC - PubMed
    1. Shearer JE, Jones R, Parker R, et al. The natural history of advanced chronic liver disease defined by transient elastography. Clin Gastroenterol Hepatol. 2023. 10.1016/j.cgh.2022.03.015. - PubMed
    1. Trebicka J, Hernaez R, Shawcross DL, et al. Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers. Gut. 2024;73(6):1015–24. 10.1136/gutjnl-2023-330584. - PMC - PubMed
    1. Segna D, Mendoza YP, Lange NF, et al. Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after Baveno VII - an update. Dig Liver Dis. 2023;55(3):326–35. 10.1016/j.dld.2022.10.009. - PubMed

LinkOut - more resources